PD-L1/PD-1 checkpoint inhibitors are gradually becoming one of the main therapeutic agents for treating various cancer types including lung cancer [106, 107], gastrointestinal cancer [108, 109], melanoma [110, 111], among others. This evidence concerns the gene CD274 and melanoma.